Avonex approval application Food and Drug Administration, 31 Jan 2003 Accessed on 15 Mar 2012 from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm086060.pdf.
Rebif approval application Food and Drug Administration, May 2003 Accessed on 12 Mar 2012 from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm106178.pdf.
ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers. Alam J, Goelz S, Rioux P, Scaramucci J, Jones W, McAllister A, Campion M, Rogge M Pharm Res. 1997 Apr; 14(4):546-9. PMID: 9144748. Abstract
Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J J Interferon Cytokine Res. 2000 Oct; 20(10):857-66. PMID: 11054273. Abstract
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Munafo A, Trinchard-Lugan I, Nguyen TX, Buraglio M Eur J Neurol. 1998 Mar; 5(2):187-193. PMID: 10210831. Abstract
Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. de Andrés C, Aristimuño C, de Las Heras V, Martínez-Ginés LM, Bartolomé M, Arroyo R, Navarro J, Giménez-Roldán S, Fernández-Cruz E, Sánchez-Ramón S J Neuroimmunol. 2007 Jan; 182(1-2):204-11. Epub 2006 Dec 08. PMID: 17157927. Abstract
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach? Chofflon M BioDrugs. 2005; 19(5):299-308. PMID: 16207071. Abstract
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis. Sanford M, Lyseng-Williamson KA Drugs. 2011 Oct 1; 71(14):1865-91. PMID: 21942977. Abstract
IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S J Immunol. 2009 Mar 15; 182(6):3928-36. PMID: 19265172. Abstract
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro. Kraus J, Voigt K, Schuller AM, Scholz M, Kim KS, Schilling M, Schäbitz WR, Oschmann P, Engelhardt B Mult Scler. 2008 Jul; 14(6):843-52. Epub 2008 May 27. PMID: 18505778. Abstract
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, Kuenz B, Lutterotti A, Berger T, Deisenhammer F Mult Scler. 2011 Oct 19. PMID: 22013146. Abstract
Alpha/beta interferon is a neuronal growth factor. Plioplys AV, Massimini N Neuroimmunomodulation. 1995 Jan-Feb; 2(1):31-5. PMID: 7614258. Abstract
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. Boutros T, Croze E, Yong VW J Neurochem. 1997 Sep; 69(3):939-46. PMID: 9282915. Abstract
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA Mult Scler. 2010 May; 16(5):588-96. Epub 2010 Feb 18. PMID: 20167591. Abstract
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L, Traboulsee A, Constantinescu C, Erälinna J-P, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, et al. Neurology. 2006 Sep 26; 67(6):944-53. PMID: 17000959. Abstract
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ Neurology. 2003 Jan 14; 60(1):44-51. PMID: 12525716. Abstract
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS(SPECTRIMS) Study Group Neurology. 2001 Jun 12; 56(11):1496-504. PMID: 11402106. Abstract
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Li DK, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group Neurology. 2001 Jun 12; 56(11):1505-13. PMID: 11402107. Abstract
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW N Engl J Med. 2000 Sep 28; 343(13):898-904. PMID: 11006365. Abstract
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 Nov 7; 352(9139):1498-504. PMID: 9820297. Abstract
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al. Ann Neurol. 1996 Mar; 39(3):285-94. PMID: 8602746. Abstract
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ... Schwid SR, Panitch HS Clin Ther. 2007 Sep; 29(9):2031-48. PMID: 18035202. Abstract
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, et al. Neurology. 2006 Apr 11; 66(7):1056-60. Epub 2006 Mar 01. PMID: 16510769. Abstract
Avonex drug warning letter, severe hypatic injury Food and Drug Administration, Mar 2005 Accessed on 15 Mar 2012 from http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164412.pdf.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease ClinicalTrials.gov, March 2005 Accessed on 13 Dec 2011 from http://clinicaltrials.gov/ct2/show/NCT01075763.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) ClinicalTrials.gov, 3 Mar 2008 Accessed on 15 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00001785.
Safety Study of Interferon Beta-1a for Acute Stroke ClinicalTrials.gov, 3 Jun 2011 Accessed on 15 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00097318.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy, et al. Neurology. 2002 Nov 26; 59(10):1496-506. PMID: 12451188. Abstract
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, et al. Arch Neurol. 2005 May; 62(5):785-92. PMID: 15883267. Abstract
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P Mult Scler. 2012 May 8. PMID: 22570359. Abstract
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis Genzyme, 11 Jul 2011 Accessed on 6 Dec 2011 from http://www.businesswire.com/news/genzyme/20110710005114/en.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis Sanofi, 11 Nov 2011 Accessed on 7 Dec 2011 from http://en.sanofi.com/Images/29137_20111114_CARE_en.pdf.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. CAMMS223 Trial Investigators, Coles AJ, Compston ADS, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK N Engl J Med. 2008 Oct 23; 359(17):1786-801. PMID: 18946064. Abstract
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass A D-D, Wynn DR, Margolin DH, Lake SL, et al. Lancet Neurol. 2011 Apr; 10(4):338-48. PMID: 21397567. Abstract
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease Genzyme, 10 Apr 2010 Accessed on 6 Dec 2011 from http://www.businesswire.com/news/genzyme/20100414005228/en.
Interferon beta for secondary progressive multiple sclerosis. La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, Filippini G Cochrane Database Syst Rev. 2012; 1:CD005181. PMID: 22258960. Abstract
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A Eur J Clin Pharmacol. 2012 Apr; 68(4):441-8. Epub 2011 Nov 05. PMID: 22057838. Abstract
Editors' Pick Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. Shirani A, Zhao Y, Karim M E, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H JAMA. 2012 Jul 18; 308(3):247-56. Epub 1969 Dec 31. PMID: 22797642. Abstract
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx ClinicalTrials.gov, 18 Apr 2012 Accessed on 23 Jul 2012 from http://www.clinicaltrials.gov/ct2/show/NCT00211887.
CombiRx for MS not better than monotherapy Otto AM, Family Practice News, 16 Jul 2012 Accessed on 23 Jul 2012 from http://www.familypracticenews.com/news/more-top-news/single-view/combirx-for-ms-not-better-than-monotherapy/dd2e57672c1b60f9b1c27729a5800e12.html.
Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, Perini P, Gallo P Mult Scler. 2012 Apr; 18(4):418-24. Epub 2011 Jan 12. PMID: 21228025. Abstract
Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Lu E, Wang B W, Guimond C, Synnes A, Sadovnick D, Tremlett H Neurology. 2012 Aug 29. PMID: 22933738. Abstract
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. Khan O, Bao F, Shah M, Caon C, Tselis A, Bailey R, Silverman B, Zak I J Neurol Sci. 2012 Jan 15; 312(1-2):7-12. Epub 2011 Sep 13. PMID: 21920559. Abstract
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Hellwig K, Haghikia A, Rockhoff M, Gold R Ther Adv Neurol Disord. 2012 Sep; 5(5):247-53. PMID: 22973421. Abstract
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Zivadinov R, Ramanathan M, Ambrus J, Hussein S, Ramasamy DP, Dwyer MG, Bergsland N, Minagar A, Weinstock-Guttman B Neurol Res. 2012 Oct; 34(8):761-9. PMID: 22971466. Abstract
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA Curr Med Res Opin. 2012 May; 28(5):767-80. Epub 2012 Apr 24. PMID: 22462530. Abstract
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Portaccio E, Stromillo M, Goretti B, Hakiki B, Giorgio A, Rossi F, De Leucio A, De Stefano N, Amato MP Eur J Neurol. 2012 Oct 11. PMID: 23057658. Abstract
Editors' Pick Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, et al. Lancet. 2012 Oct 31. PMID: 23122652. Abstract
Editors' Pick Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, et al. Lancet. 2012 Oct 31. PMID: 23122650. Abstract
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. Meca-Lallana JE, Balseiro JJ, Lacruz F, Guijarro C, Sanchez O, Cano A, Costa-Frossard L, Hernández-Clares R, Sanchez-De la Rosa R, Escala Study Group J Neurol Sci. 2012 Apr 15; 315(1-2):123-8. Epub 2011 Nov 30. PMID: 22133480. Abstract
Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity. Barnard JG, Babcock K, Carpenter JF J Pharm Sci. 2012 Dec 11. PMID: 23233295. Abstract
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a) EMD Serono, 3 Jan 2013 Accessed on 7 Jan 2013 from http://www.emdserono.com/cmg.emdserono_us/en/images/121204-183958_Rebif%20Rebidose%20Approval%20Press%20Release_FINAL_tcm115_104286.pdf.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Gavasso S, Torkildsen Ø, Marøy TH, Ulvestad E, Myhr K-M, Vedeler CA Acta Neurol Scand Suppl. 2012(195):84-9. PMID: 23278662. Abstract
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. Cadavid D, Jurgensen S, Lee S PLoS One. 2013; 8(1):e53297. Epub 2013 Jan 04. PMID: 23308186. Abstract
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease. Pauwels I, Cosemans L, Boonen S, Dubois B, Goris A Mult Scler. 2013 Jan 16. PMID: 23325590. Abstract
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis Biogen Idec, 24 Jan 2013 Accessed on 29 Jan 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1777510.
Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis. J Med Econ. 2013 Feb 7. PMID: 23391123. Abstract
Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. Praksova P, Stourac P, Bednarik J, Vlckova E, Mikulkova Z, Michalek J J Neurol Sci. 2012 Aug 15; 319(1-2):18-23. Epub 2012 Jun 05. PMID: 22676847. Abstract
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Romeo M, Martinelli-Boneschi F, Rodegher M, Esposito F, Martinelli V, Comi G, San Raffaele Multiple Sclerosis Clinical Group Eur J Neurol. 2013 Feb 20. PMID: 23425504. Abstract
Editors' Pick Randomized study combining interferon & glatiramer acetate in multiple sclerosis. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS, for the CombiRx Investigators. Ann Neurol. 2013 Feb 19. Epub 1969 Dec 31. PMID: 23424159. Abstract
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Orvain C, Augusto J-F, Besson V, Marc G, Coppo P, Subra J-F, Sayegh J Int Urol Nephrol. 2013 Feb 24. Epub 2013 Feb 24. PMID: 23435773. Abstract
Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients. Martino S, Montesano S, di Girolamo I, Tiribuzi R, Di Gregorio M, Orlacchio A, Datti A, Calabresi P, Sarchielli P, Orlacchio A Mult Scler. 2013 Feb 25. PMID: 23439581. Abstract
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status Biogen Idec, 18 Mar 2013 Accessed on 21 Mar 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1797077.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting Biogen Idec, 20 Mar 2013 Accessed on 21 Mar 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1798258.
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC Front Immunol. 2013; 4:63. Epub 2013 Mar 13. PMID: 23493880. Abstract
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies Novartis, 21 Mar 2013 Accessed on 25 Mar 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1686799.shtml.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al. N Engl J Med. 2010 Feb 4; 362(5):402-15. Epub 2010 Jan 20. PMID: 20089954. Abstract
Extension CombiRx data show no benefit of combined MS drugs Medscape Medical News, 21 Mar 2013 Accessed on 25 Mar 2013 from http://www.medscape.com/viewarticle/781153.
Editors' Pick The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. Jokubaitis VG, Spelman T, Lechner-Scott J, Barnett M, Shaw C, Vucic S, Liew D, Butzkueven H, Slee M, Slee M PLoS One. 2013; 8(3):e59694. Epub 2013 Mar 19. PMID: 23527252. Abstract
Interferon β for secondary progressive multiple sclerosis: a systematic review. La Mantia L, Vacchi L, Rovaris M, Di Pietrantonj C, Ebers G, Fredrikson S, Filippini G J Neurol Neurosurg Psychiatry. 2013 Apr; 84(4):420-6. Epub 2012 Sep 05. PMID: 22952326. Abstract
Editors' Pick Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, Pelletier J, Eckert B, Häring DA, Francis G J Neurol. 2013 Apr 30. PMID: 23632946. Abstract
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis Biogen Idec, 21 May 2013 Accessed on 31 May 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1822494.
Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies. Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Borter E, Traber M Eur Neurol. 2013 May 14; 70(1):35-41. Epub 2013 May 14. PMID: 23689307. Abstract
Editors' Pick Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis. Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, van Pesch V, et al. PLoS One. 2013; 8(5):e63480. Epub 2013 May 21. PMID: 23704913. Abstract
Effects of Interferon β-1a and Interferon β-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study. Stępień A, Chalimoniuk M, Lubina-Dąbrowska N, Chrapusta SJ, Galbo H, Langfort J Neuroimmunomodulation. 2013 May 24; 20(4):213-222. Epub 2013 May 24. PMID: 23711618. Abstract
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis Novartis, 5 Jun 2013 Accessed on 8 Jun 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1707070.shtml.
Alemtuzumab benefits hard-to-treat MS patients Anderson P, Medscape Today, 2 Jun 2013 Accessed on 8 Jun 2013 from http://www.medscape.com/viewarticle/805173.
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G, Giovane C D, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G Cochrane Database Syst Rev. 2013 Jun 6; 6:CD008933. PMID: 23744561. Abstract
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study. Singer B, Bandari D, Cascione M, LaGanke C, Huddlestone J, Bennett R, Dangond F, REFORMS Study Group BMC Neurol. 2012; 12:154. Epub 2012 Dec 06. PMID: 23216674. Abstract
RNF and Betaseron® Tolerability Study (REFORMS) ClinicalTrials.gov, 8 Sep 2010 Accessed on 20 Jun 2013 from http://www.clinicaltrials.gov/ct2/show/NCT00428584.
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators. Peelen E, Thewissen M, Knippenberg S, Smolders J, Muris A-H, Menheere P, Tervaert CJW, Hupperts R, Damoiseaux J J Neuroimmunol. 2013 May 15; 258(1-2):77-84. Epub 2013 Mar 19. PMID: 23517930. Abstract
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review Biogen Idec, 19 Jul 2013 Accessed on 25 Jul 2013 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1839270.
Biogen Idec's long-acting beta interferon moves ahead in MS PMLiVE, 23 Jul 2013 Accessed on 25 Jul 2013 from http://www.pmlive.com/pharma_news/biogen_idecs_long-acting_beta_interferon_moves_ahead_in_ms_491668.
Editors' Pick An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL Sci Transl Med. 2012 Sep 26; 4(153):153ra131. PMID: 23019656. Abstract
Editors' Pick A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E J Clin Pharm Ther. 2013 Aug 20. PMID: 23957759. Abstract
Editors' Pick Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla A, Karkare SU, Balderston McGuiness C, Korn JR Curr Med Res Opin. 2013 Oct 1. Epub 1969 Dec 31. PMID: 24059944. Abstract
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a) Biogen Idec, 1 Oct 2013 Accessed on 5 Oct 2013 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1860099.
Low-contrast visual tests reveal better alemtuzumab efficacy Keller DM, Medscape, 8 Oct 2013 Accessed on 10 Oct 2013 from http://www.medscape.com/viewarticle/812227.
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW BMC Neurol. 2013 Oct 4; 13(1):138. Epub 2013 Oct 04. PMID: 24093542. Abstract
Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review. Fragoso YD, Adoni T, Alves-Leon SV, Azambuja ND, Barreira AA, Brooks JBB, Carneiro DSD, Carvalho MJ, Claudino R, Comini-Frota ER, et al. CNS Drugs. 2013 Oct 10. PMID: 24114585. Abstract
Development of oral immunomodulatory agents in the management of multiple sclerosis. Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA Drug Des Devel Ther. 2011; 5:255-74. Epub 2011 May 10. PMID: 21625416. Abstract
A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE) ClinicalTrials.gov, 10 Oct 2011 Accessed on 5 Jan 2012 from http://clinicaltrials.gov/show/NCT00883337.
Teriflunomide modest help but safe for MS Medpage Today, 4 Jun 2012 Accessed on 12 Jun 2012 from http://www.medpagetoday.com/MeetingCoverage/CMSC-ACTRIMS/33059.
Editors' Pick Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Vermersch P, Czlonkowska A, Grimaldi LME, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, et al. Mult Scler. 2013 Oct 14. PMID: 24126064. Abstract
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence. Di Filippo M, Tozzi A, Tantucci M, Arcangeli S, Chiasserini D, Ghiglieri V, de Iure A, Calabresi P Neurobiol Dis. 2013 Oct 14. PMID: 24135008. Abstract
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM, Johnson BH, Wenten M, Watson C Clin Ther. 2013 Oct; 35(10):1501-12. PMID: 24139422. Abstract
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis. Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH J Clin Endocrinol Metab. 2013 Oct 29. PMID: 24170099. Abstract
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO) ClinicalTrials.gov, 28 Oct 2013 Accessed on 6 Nov 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01975298.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis Active Biotech, 4 Nov 2013 Accessed on 6 Nov 2013 from http://www.activebiotech.com/press-releases-1?pressurl=http://cws.huginonline.com/A/1002/PR/201311/1740139.xml.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months Carroll D, Daily Finance, 31 Oct 2013 Accessed on 6 Nov 2013 from http://www.dailyfinance.com/2013/10/31/3-blockbuster-drugs-losing-patent-protection-in-20/.
Editors' Pick Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui M K, Taneja A, Deniz B Curr Med Res Opin. 2013 Nov 7. Epub 1969 Dec 31. PMID: 24195574. Abstract
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST) ClinicalTrials.gov, 13 Sep 2012 Accessed on 25 Nov 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01405872.
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients News-Medical.net, 13 Nov 2013 Accessed on 25 Nov 2013 from http://www.news-medical.net/news/20131113/New-data-show-positive-results-from-Phase-4-study-of-Avonex-Pen-for-treatment-of-RRMS-patients.aspx.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D Curr Med Res Opin. 2013 Dec 5. PMID: 24289170. Abstract
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon. Zare N, Zarkesh-Esfahani S H, Gharagozloo M, Shaygannejad V J Korean Med Sci. 2013 Dec; 28(12):1801-6. Epub 2013 Nov 26. PMID: 24339712. Abstract
Teriflunomide in multiple sclerosis: Added benefit not proven Institute for Quality and Efficiency in Health Care, 2 Jan 2014 Accessed on 10 Jan 2014 from https://www.iqwig.de/en/press/press_releases/press_releases/teriflunomide_in_multiple_sclerosis_added_benefit_not_proven.5368.html.
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr K-M Mult Scler. 2014 Jan 16. PMID: 24436455. Abstract 1 member recommends
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database. Fox RJ, Salter AR, Tyry T, Sun J, You X, Laforet G, Campagnolo D Int J MS Care. 2013 Winter; 15(4):194-201. PMID: 24453783. Abstract
Relationship between disease-modifying therapy and depression in multiple sclerosis. Kirzinger SS, Jones J, Siegwald A, Crush A B Int J MS Care. 2013 Fall; 15(3):107-12. PMID: 24453772. Abstract
Editors' Pick Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla AA, Karkare SU, Balderston McGuiness C, Korn JR PLoS One. 2014; 9(2):e88472. Epub 2014 Feb 06. PMID: 24516663. Abstract
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, et al. Mult Scler. 2014 Feb 10. PMID: 24515732. Abstract
Change in the clinical development program for laquinimod Active Biotech, 19 Feb 2014 Accessed on 20 Feb 2014 from http://www.activebiotech.com/press-releases-1?pressurl=http://cws.huginonline.com/A/1002/PR/201402/1763038.xml.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, On behalf of the BRAVO Study Group J Neurol. 2014 Feb 18. Epub 2014 Feb 18. PMID: 24535134. Abstract
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients. Nischwitz S, Faber H, Sämann PG, Domingues HS, Krishnamoorthy G, Knop M, Müller-Sarnowski F, Yassouridis A, Weber F Acta Neurol Scand. 2014 Jan 25. PMID: 24571587. Abstract
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a) Biogen Idec, 18 Mar 2014 Accessed on 18 Mar 2014 from https://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2293&M=NewsV2&PID=61997.
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs. Lu E, Zhu F, Zhao Y, van der Kop M, Synnes A, Dahlgren L, Sadovnick DA, Traboulsee A, Tremlett H CNS Drugs. 2014 Mar 19. PMID: 24643915. Abstract
Thrombotic microangiopathy associated with use of interferon-beta. Olea T, Díaz-Mancebo R, Picazo M-L, Martínez-Ara J, Robles A, Selgas R Int J Nephrol Renovasc Dis. 2012; 5:97-100. Epub 2012 Jun 15. PMID: 22815645. Abstract
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom. Agius M, Meng X, Chin P, Grinspan A, Hashmonay R CNS Neurosci Ther. 2014 Mar 31. PMID: 24684973. Abstract
Editors' Pick MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Fox RJ, Cree BAC, De Sèze J, Gold R, Hartung H-P, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, et al. Neurology. 2014 Apr 9. Epub 2014 Mar 28. PMID: 24682966. Abstract
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R Exp Neurol. 2014 Apr 13. PMID: 24731948. Abstract
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008. Tsai C-P, Lee C T-C Clin Drug Investig. 2013 Jul 17. PMID: 23861171. Abstract
Thrombotic microangiopathy associated with interferon beta. Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J, Evans S, Jackson A, Chandran S N Engl J Med. 2014 Mar 27; 370(13):1270-1. PMID: 24670186. Abstract
Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. Menzin J, Caon C, Nichols C, White L A, Friedman M, Pill MW J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S24-40. PMID: 23383731. Abstract
Biogen Idec to present new two-year data from the PLEGRIDY™ (peginterferon beta-1a) Phase III advance study at AAN annual meeting Biogen Idec, 29 Apr 2014 Accessed on 15 May 2014 from https://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2319&M=NewsV2&PID=61997.
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis Oakes K, HCP Live, 30 Apr 2014 Accessed on 15 May 2014 from http://www.hcplive.com/conferences/2014-aan/Study-Shows-Promising-Efficacy-for-Peginterferon-Beta-1a-in-Multiple-Sclerosis.
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, on behalf of the TRANSFORMS study group Mult Scler. 2014 May 8. PMID: 24812043. Abstract
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a. Mishra A, Guindi M, Kandel G, Streutker CJ Histopathology. 2014 May 5. PMID: 24796493. Abstract
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Kulakova OG, Tsareva E Y, Lvovs D, Favorov AV, Boyko AN, Favorova OO Pharmacogenomics. 2014 Apr; 15(5):679-85. PMID: 24798724. Abstract
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss GlobeNewswire, 23 Apr 2014 Accessed on 17 May 2014 from http://www.nasdaq.com/press-release/new-data-at-aan-to-confirm-efficacy-of-novartis-gilenya-across-four-key-measures-of-ms-disease-20140423-00020.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis ClinicalTrials.gov, 6 May 2014 Accessed on 17 May 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01892722.
Interferon beta treatment of multiple sclerosis increases serum interleukin-7. Lundström W, Hermanrud C, Sjöstrand M, Brauner S, Wahren-Herlenius M, Olsson T, Karrenbauer V, Hillert J, Fogdell-Hahn A Mult Scler. 2014 May 12. PMID: 24821684. Abstract
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S J Neuroimmunol. 2014 Apr 24. PMID: 24814390. Abstract
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union Biogen Idec, 23 May 2014 Accessed on 26 May 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2332&M=NewsV2&PID=61997.
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial. Mokhber N, Azarpazhooh A, Orouji E, Rao SM, Khorram B, Sahraian M A, Foroghipoor M, Gharavi M M, Kakhi S, Nikkhah K, et al. J Neurol Sci. 2014 Feb 4. PMID: 24841321. Abstract
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. Pecori C, Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Sturchio A, De Giglio L, Pozzilli C, et al. BMC Neurol. 2014 May 26; 14(1):114. Epub 2014 May 26. PMID: 24884599. Abstract
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse Remitting Multiple Sclerosis Abbot, 24 May 2010 Accessed on 3 Dec 2011 from http://www.abbott.com/news-media/press-releases/Press_Release_0863.htm.
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis Biogen Idec, 16 Jun 2014 Accessed on 19 Jun 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2358&M=NewsV2&PID=61997.
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE)) ClinicalTrials.gov, 12 Sep 2013 Accessed on 19 Jun 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01064401.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz. Erhamamcı S, Horasanlı B, Aktaş A Mol Imaging Radionucl Ther. 2014 Jun; 23(2):43-7. Epub 2014 Jun 05. PMID: 24963444. Abstract
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients. O'Connell KE, Mok T, Sweeney B, Ryan AM, Dev KK Autoimmunity. 2014 Jun 30:1-7. PMID: 24974887. Abstract
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(5):65-9. PMID: 24988963. Abstract
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis. Hou Y, Ryu C H, Jun J A, Kim S M, Jeong C H, Jeun S-S J Neuroimmunol. 2014 Jun 20. PMID: 25005115. Abstract
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, Balderston McGuiness C, Korn JR J Med Econ. 2014 Jul 23:1-12. PMID: 25019581. Abstract
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis Biogen Idec, 23 Jul 2014 Accessed on 24 Jul 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2367&M=NewsV2&PID=61997.
Treatment satisfaction in multiple sclerosis. Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC Int J MS Care. 2014 Summer; 16(2):68-75. PMID: 25061430. Abstract
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN) ClinicalTrials.gov, 25 Jul 2014 Accessed on 4 Aug 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01332019.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study. Seddighzadeh A, Hung S, Selmaj K, Cui Y, Liu S, Sperling B, Calabresi PA Expert Opin Drug Deliv. 2014 Jul 29:1-8. PMID: 25073663. Abstract
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A Cochrane Database Syst Rev. 2014; 7:CD009333. Epub 1969 Dec 31. PMID: 25062935. Abstract
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis. Ortega-Madueño I, Garcia-Montojo M, Dominguez-Mozo M I, Garcia-Martinez A, Arias-Leal A M, Casanova I, Arroyo R, Alvarez-Lafuente R PLoS One. 2014; 9(8):e104836. Epub 2014 Aug 11. PMID: 25110949. Abstract
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis Biogen Idec, 15 Aug 2014 Accessed on 19 Aug 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2368&M=NewsV2&PID=61997.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study. Galuppo M, Giacoppo S, Sessa E, Bramanti P, Mazzon E J Neurol Sci. 2014 Jul 30. PMID: 25115502. Abstract
In vitro Biological Characterization of IFN-β-1a major Glycoforms. Mastrangeli R, Rossi M, Mascia M, Palinsky W, Datola A, Terlizzese M, Bierau H Glycobiology. 2014 Aug 11. PMID: 25117008. Abstract
The Role of Endogenous IFN-β in the Regulation of Th17 Responses in Patients with Relapsing-Remitting Multiple Sclerosis. Tao Y, Zhang X, Chopra M, Kim M-J, Buch KR, Kong D, Jin J, Tang Y, Zhu H, Jewells V, et al. J Immunol. 2014 May 21. PMID: 24850724. Abstract
EU regulator warns on possible MS drugs side effects Reuters, 20 Aug 2014 Accessed on 25 Aug 2014 from http://www.reuters.com/article/2014/08/20/ms-drugs-sideeffects-idUSL5N0QQ3T620140820.
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, et al. Neurology. 2002 Sep 10; 59(5):679-87. PMID: 12221157. Abstract
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, et al. Arch Neurol. 2001 Jun; 58(6):961-7. PMID: 11405811. Abstract
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis. Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA JAMA Neurol. 2014 Sep 1. PMID: 25178496. Abstract
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, et al. N Engl J Med. 2006 Mar 2; 354(9):911-23. PMID: 16510745. Abstract
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function. Hu X, Seddighzadeh A, Stecher S, Zhu Y, Goyal J, Matson M, Marbury T, Smith W, Nestorov I, Hung S J Clin Pharmacol. 2014 Sep 4. PMID: 25187030. Abstract
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients Biogen Idec, 11 Sep 2014 Accessed on 15 Sep 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2375&M=NewsV2&PID=61997.
Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process) Biogen Idec, 12 Sep 2014 Accessed on 15 Sep 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2377&M=NewsV2&PID=61997.
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, Duddy M, Dobson C BMJ Open. 2014; 4(1):e004073. PMID: 24441054. Abstract
Beta-Interferon, Glatiramer Acetate Cost-Effective in MS Hughes S, Medscape Medical News, 18 Sep 2014 Accessed on 23 Sep 2014 from http://www.medscape.com/viewarticle/831921.
Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses. Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N Adv Ther. 2014 Sep 23. Epub 2014 Sep 23. PMID: 25245812. Abstract
Generic interferon-beta Fraunhofer Institute for Interfacial Engineering and Biotechnology Accessed on 3 Oct 2014 from http://www.igb.fraunhofer.de/en/competences/molecular-biotechnology/therapeutic-proteins/generic-interferon.html.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study. Balak D M, Hengstman G J, Hajdarbegovic E, van den Brule R J, Hupperts RMM, Thio H B BMC Neurol. 2013 Oct 16; 13(1):146. Epub 2013 Oct 16. PMID: 24131589. Abstract
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study. Hu X, Cui Y, White J, Zhu Y, Deykin A, Nestorov I, Hung S Br J Clin Pharmacol. 2014 Sep 29. PMID: 25265472. Abstract
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report. Blancas I, Cárdenas N, Delgado M, Jurado J M, Legeren M, Villaescusa A, Galvez F, Yelamos M Oncol Lett. 2014 Nov; 8(5):2179-2182. Epub 2014 Sep 10. PMID: 25289098. Abstract
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis. Zhang X, Hay JW, Niu X CNS Drugs. 2014 Oct 19. PMID: 25326785. Abstract
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. Darbà J, Kaskens L, Sánchez-de la Rosa R J Med Econ. 2014 Mar; 17(3):215-22. PMID: 24494728. Abstract
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis. Thomas K, Dietze K, Wehner R, Metz I, Tumani H, Schultheiß T, Günther C, Schäkel K, Reichmann H, Brück W, et al. Neurol Neuroimmunol Neuroinflamm. 2014 Oct; 1(3):e33. Epub 2014 Sep 18. PMID: 25340085. Abstract
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Kinkel PR, Kollman C, O'Connor P, Murray T J, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, et al. Neurology. 2006 Mar 14; 66(5):678-84. Epub 2006 Jan 25. PMID: 16436649. Abstract
Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurol Kinkel PR, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH, Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators Arch Neurol. 2012 Feb; 69(2):183-90. Epub 2011 Oct 10. PMID: 21987393. Abstract
Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Simon JH, Kinkel RP, Kollman C, O'Connor P, Fisher E, You X, Hyde R, for the CHAMPIONS Investigators Group Mult Scler. 2014 Oct 24. PMID: 25344370. Abstract
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.] Bakhtiiarova KZ, Bragina OV, Vlasov IV, Greshnova IV, Evdoshenko EP, Ivanishenkova EI, Kairbekova EI, Karnaukhova EN, Korotkevich NA, Leliukhina AV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(8):39-45. PMID: 25345629. Abstract
Assessment of cancer risk with β-interferon treatment for multiple sclerosis. Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H J Neurol Neurosurg Psychiatry. 2014 Mar 4. PMID: 24594506. Abstract
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis? Lewis SM, McMillan GP, Hutter M, Folmer RL, Wilmington D, Casiana L, Fitzpatrick M, Lilly DJ, Bourdette D, Overs S, et al. J Neurosci Nurs. 2014 Dec; 46(6):351-60. PMID: 25365049. Abstract
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis. Sternberg Z, Sternberg D, Drake A, Chichelli T, Yu J, Hojnacki D J Neuroimmunol. 2014 Sep 15; 274(1-2):197-201. Epub 2014 Jul 15. PMID: 25064498. Abstract
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Beaber B E, Chi MD, Brara S M, Zhang J L, Langer-Gould AM Perm J. 2014 Winter; 18(1):9-13. PMID: 24626066. Abstract
Editors' Pick Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, et al. Mult Scler. 2014 Dec 5. PMID: 25480857. Abstract
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M, Comi G, Rovaris M, et al. J Immunol Res. 2014; 2014:961863. Epub 2014 Mar 26. PMID: 24741637. Abstract
Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung H-P, Jarius S, Aktas O BMC Neurol. 2014 Dec 17; 14(1):247. Epub 2014 Dec 17. PMID: 25516429. Abstract
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study Novartis, 11 Jun 2012 Accessed on 12 Jun 2012 from http://www.novartis.com/newsroom/media-releases/en/2012/1618585.shtml.
Switching to Gilenya® (fingolimod) from a standard interferon offers sustained freedom from disease activity for people with relapsing remitting multiple sclerosis Pharmiweb, 10 Jun 2013 Accessed on 20 Jun 2013 from http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=75633#.UcNxHo6-K4k.
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G Contemp Clin Trials. 2014 Dec 26. PMID: 25545026. Abstract
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A J Neurol Neurosurg Psychiatry. 2014 Dec 30. PMID: 25550414. Abstract
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S BMC Neurol. 2014 Dec 31; 14(1):1058. Epub 2014 Dec 31. PMID: 25551571. Abstract
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. Prosperini L, Mancinelli C R, Pozzilli C, Grasso M G, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, et al. Eur Neurol. 2014 Jan 25; 71(5-6):135-143. Epub 2014 Jan 25. PMID: 24480868. Abstract
Editors' Pick IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity. Schubert RD, Hu Y, Kumar G, Szeto S, Abraham P, Winderl J, Guthridge JM, Pardo G, Dunn J, Steinman L, et al. J Immunol. 2015 Mar 1; 194(5):2110-2116. Epub 2015 Feb 02. PMID: 25646307. Abstract
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature. Villamil A, Mullen E, Casciato P, Gadano A Ann Hepatol. 2015 Mar-Apr; 14(2):273-80. PMID: 25671839. Abstract
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, et al. JAMA Neurol. 2015 Feb 9:1-10. PMID: 25665031. Abstract
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis. Evans R, Rudd P, Bass P, Harber M BMJ Case Rep. 2014; 2014. PMID: 24503666. Abstract
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis. Harari D, Orr I, Rotkopf R, Baranzini SE, Schreiber G Hum Mol Genet. 2015 Feb 26. PMID: 25721402. Abstract
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study. Rinaldi F, Perini P, Atzori M, Favaretto A, Seppi D, Gallo P Mult Scler Int. 2015; 2015:369348. Epub 2015 Feb 23. PMID: 25802758. Abstract
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways? Fine D, Dattani A, Moreira I, Giovannoni G, Marta M Mult Scler Relat Disord. 2015 Jan; 4(1):88-91. Epub 2014 Nov 28. PMID: 25787060. Abstract
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse. Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H Mult Scler Relat Disord. 2015 Jan; 4(1):75-82. Epub 2014 Oct 07. PMID: 25787057. Abstract
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, et al. Lancet Neurol. 2015 Apr 1. PMID: 25841667. Abstract
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, et al. PLoS One. 2014; 9(3):e91098. Epub 2014 Mar 13. PMID: 24625687. Abstract
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial ClinicalTrials.gov, 2 Aug 2013 Accessed on 16 Apr 2015 from https://clinicaltrials.gov/show/NCT01085318.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly. Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F J Neuroimmunol. 2015 Apr 15; 281:44-50. Epub 2015 Mar 05. PMID: 25867467. Abstract
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. Zhornitsky S, Greenfield J, Koch MW, Patten SB, Harris C, Wall W, Alikhani K, Burton J, Busche K, Costello F, et al. PLoS One. 2015; 10(4):e0123824. Epub 2015 Apr 13. PMID: 25867095. Abstract
Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients Novartis, 21 Apr 2015 Accessed on 21 Apr 2015 from http://www.novartis.com/newsroom/media-releases/en/2015/1912676.shtml.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients Biogen, 21 Apr 2015 Accessed on 21 Apr 2015 from http://biogen.newshq.businesswire.com/press-release/neurology/plegridy-peginterferon-beta-1a-three-year-data-presented-aan-annual-meeting-.
Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome reports with SC interferon beta-1a. Amor AF, Trochanov A, Johnson J Mult Scler Relat Disord. 2014 Nov; 3(6):756-7. Epub 2014 Nov 21. PMID: 25891600. Abstract
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl Khatri BO, Pelletier J, Kappos L, Hartung H-P, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, et al. Mult Scler Relat Disord. 2014 May; 3(3):355-63. Epub 2013 Dec 12. PMID: 25876473. Abstract
Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome. Kinkel RP, Simon JH, O'Connor P, Hyde R, Pace A Mult Scler Relat Disord. 2014 Nov; 3(6):712-9. Epub 2014 Aug 27. PMID: 25891550. Abstract
Comparative efficacy of switching to natalizumab in active multiple sclerosis. Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, et al. Ann Clin Transl Neurol. 2015 Apr; 2(4):373-87. Epub 2015 Feb 27. PMID: 25909083. Abstract
Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a. Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, et al. Eur J Neurol. 2015 Apr 22. PMID: 25904020. Abstract
Biogen Idec Becomes Biogen Biogen, 23 Mar 2015 Accessed on 7 Apr 2015 from http://biogen.newshq.businesswire.com/press-release/corporate/biogen-idec-becomes-biogen.
Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Røsjø E, Myhr K-M, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, et al. J Neuroimmunol. 2015 Mar 15; 280:21-8. Epub 2015 Feb 11. PMID: 25773151. Abstract
Editors' Pick A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, Brambilla P, Liberatore G, Guaschino C, Romeo M, et al. Ann Neurol. 2015 Apr 25. PMID: 25914168. Abstract
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui M K, Kinter E PLoS One. 2015; 10(6):e0127960. Epub 2015 Jun 03. PMID: 26039748. Abstract
Novel MS Drug Offers Good Functional Outcomes Fiore K, MedPage Today, 2 Jun 2015 Accessed on 9 Jun 2015 from http://www.medpagetoday.com/MeetingCoverage/CMSC/51896.
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Bayas A, Ouallet J C, Kallmann B, Hupperts R, Fulda U, Marhardt K, SMART study group Expert Opin Drug Deliv. 2015 Jun 22:1-12. PMID: 26098143. Abstract
A Study of Ocrelizumab in Comparison with Interferon Beta 1a (Rebif) in Patients with Relapsing Multiple Sclerosis ClinicalTrials.gov, 27 Jan 2012 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT01412333.
A Study of Ocrelizumab in Comparison with Interferon Beta 1a (Rebif) in Patients with Relapsing Multiple Sclerosis ClinicalTrials.gov, 1 Jun 2015 Accessed on 30 Jun 2015 from http://clinicaltrials.gov/ct2/show/NCT01247324.
Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years Genentech, 19 Oct 2011 Accessed on 5 Dec 2011 from http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=13627.
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis Genentech, 29 Jun 2015 Accessed on 30 Jun 2015 from http://www.gene.com/media/press-releases/14597/2015-06-29/genentechs-ocrelizumab-significantly-red.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH, Bonafede MM, Watson C CNS Drugs. 2015 Jun 26. PMID: 26113055. Abstract
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, et al. J Neurol Neurosurg Psychiatry. 2015 Jun 25. PMID: 26111826. Abstract
Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis. Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP J Interferon Cytokine Res. 2011 Mar; 31(3):337-44. Epub 2011 Jan 12. PMID: 21226608. Abstract
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Kleinschnitz C, Niemczyk G, Rehberg-Weber K, Wernsdörfer C Int J Mol Sci. 2015; 16(7):15271-86. PMID: 26154767. Abstract
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. Hansen K, Schüssel K, Kieble M, Werning J, Schulz M, Friis R, Pöhlau D, Schmitz N, Kugler J PLoS One. 2015; 10(7):e0133279. Epub 2015 Jul 27. PMID: 26214805. Abstract
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study. Lus G, Signoriello E, Maniscalco GT, Bonavita S, Signoriello S, Gallo C Eur J Neurol. 2015 Jul 26. PMID: 26212486. Abstract
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis. Fisher E, Nakamura K, Lee J-C, You X, Sperling B, Rudick RA Mult Scler. 2015 Aug 3. PMID: 26238463. Abstract
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis. Smith MY, Sabidó-Espin M, Trochanov A, Samuelson M, Guedes S, Corvino FA, Richy FF J Manag Care Spec Pharm. 2015 Aug; 21(8):650-60. PMID: 26233537. Abstract
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis PR Newswire, 13 Aug 2015 Accessed on 18 Aug 2015 from https://www.virtualpressoffice.com/publicsiteContentFileAccess?fileContentId=2102825&fromOtherPageToDisableHistory=Y&menuName=News&sId=&sInfo=.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis. Govindappa K, Sathish J, Park K, Kirkham J, Pirmohamed M Eur J Clin Pharmacol. 2015 Aug 14. Epub 2015 Aug 14. PMID: 26268445. Abstract
Editors' Pick Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. Bertoli D, Serana F, Sottini A, Cordioli C, Maimone D, Amato M P, Centonze D, Florio C, Puma E, Capra R, et al. PLoS One. 2015; 10(8):e0135441. Epub 2015 Aug 18. PMID: 26285213. Abstract
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Moccia M, Palladino R, Russo C, Massarelli M, Nardone A, Triassi M, Lugaresi A, Brescia Morra V Expert Opin Drug Deliv. 2015 Sep 15:1-7. PMID: 26371561. Abstract
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore G B, Marrosu M G, et al. Brain. 2015 Sep 11. PMID: 26362907. Abstract
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Tramacere I, Giovane C D, Salanti G, D'Amico R, Filippini G Cochrane Database Syst Rev. 2015 Sep 18; 9:CD011381. PMID: 26384035. Abstract
Novel MS Drugs Advance Gever J, MedPage Today, 4 Nov 2014 Accessed on 11 Nov 2014 from http://www.medpagetoday.com/Neurology/MultipleSclerosis/48404.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, et al. N Engl J Med. 2015 Oct 8; 373(15):1418-28. PMID: 26444729. Abstract
Ocrelizumab Bests Interferon in Relapsing-Remitting MS Fiore K, MedPage Today, 9 Oct 2015 Accessed on 13 Oct 2015 from http://www.medpagetoday.com/clinical-context/MultipleSclerosis/54020.
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. Kappos L, Kuhle J, Multanen J, Kremenchutzky M, Verdun di Cantogno E, Cornelisse P, Lehr L, Casset-Semanaz F, Issard D, Uitdehaag B M J Neurol Neurosurg Psychiatry. 2015 Sep 15. PMID: 26374702. Abstract
Editors' Pick Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Sánchez-de la Rosa R, García-Bujalance L, Meca-Lallana J Health Econ Rev. 2015 Dec; 5(1):30. Epub 2015 Oct 16. PMID: 26475277. Abstract
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Kvistad S, Myhr K-M, Holmøy T, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Løken-Amsrud KI, Lilleås F, Midgard R, et al. Mult Scler. 2014 May 19. PMID: 24842958. Abstract
Effect of vitamin D on MS activity by disease-modifying therapy class. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167. Epub 2015 Oct 29. PMID: 26568968. Abstract
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients. Fok A, Williams T, McLean CA, Butler E Mult Scler. 2015 Nov 12. PMID: 26564996. Abstract
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, et al. BMC Neurol. 2015; 15:232. Epub 2015 Nov 11. PMID: 26559139. Abstract
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand KV PLoS One. 2015; 10(11):e0143393. Epub 2015 Nov 23. PMID: 26600308. Abstract
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS. Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e176. Epub 2015 Nov 12. PMID: 26601116. Abstract
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis. Gurevich M, Miron G, Falb R Z, Magalashvili D, Dolev M, Stern Y, Achiron A BMC Neurol. 2015; 15(1):240. Epub 2015 Nov 21. PMID: 26589141. Abstract
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Kaufman M, Cree BAC, De Sèze J, Fox RJ, Gold R, Hartung H-P, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, et al. J Neurol. 2015 Feb; 262(2):326-36. Epub 2014 Nov 09. PMID: 25381458. Abstract
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta. Kozielewicz D, Pawłowska M Neurol Neurochir Pol. 2015; 49(6):451-5. Epub 2015 Sep 09. PMID: 26652882. Abstract
Direct immunomodulatory influence of IFN-β on human astrocytoma cells. Mohsenzadegan M, Fayazi M R, Abdolmaleki M, Bakhshayesh M, Seif F, Mousavizadeh K Immunopharmacol Immunotoxicol. 2015 Apr; 37(2):214-9. Epub 2015 Feb 18. PMID: 25689952. Abstract
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development. Uçar İ, Ertekin T, Nisari M, Ceylan D, Al Ö, Ülger H Folia Morphol (Warsz). 2015 Dec 29. PMID: 26711647. Abstract
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US EMD Serono, 19 Jan 2016 Accessed on 19 Jan 2016 from http://www.emdserono.com/ms.country.us/en/images/January%20NDD%202016%20release_Final_tcm115_146142.pdf?Version=.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'maison F, et al. Eur J Neurol. 2016 Jan 19. PMID: 26782663. Abstract
Drug Safety Labeling Changes US Food and Drug Administration, 13 Jan 2016 Accessed on 29 Jan 2016 from http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm480758.htm.
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study. Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, et al. Eur J Neurol. 2016 Feb 5. PMID: 26848561. Abstract
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE) ClinicalTrials.gov, 2 Dec 2013 Accessed on 12 Feb 2016 from https://www.clinicaltrials.gov/ct2/show/NCT01134627.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Paolicelli D, Cocco E, Lecce V D, Direnzo V, Moiola L, Lanzillo R, Perini P, Malucchi S, Borriello G, Portaccio E, et al. Expert Opin Drug Deliv. 2016 Mar 12:1-7. PMID: 26922837. Abstract
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X J Neuroimaging. 2016 Mar 2. PMID: 26935253. Abstract
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, et al. BMC Neurol. 2012; 12:7. Epub 2012 Mar 05. PMID: 22390218. Abstract
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study. Lugaresi A, De Robertis F, Clerico M, Brescia Morra V, Centonze D, Borghesan S, Maniscalco G T, Maniscalco G T Expert Opin Drug Deliv. 2016 Feb 24:1-5. PMID: 26909646. Abstract
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. Devonshire VA, Feinstein A, Moriarty P BMC Res Notes. 2016; 9(1):148. Epub 2016 Mar 08. PMID: 26951043. Abstract
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L, Guo S, Kinter E, Fay M J Med Econ. 2016 Mar 7:1-12. PMID: 26947984. Abstract
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJA, Strijbis EMM, Steenwijk MD, Polman CH, Pouwels PJW, Barkhof F, Geurts JJG AJNR Am J Neuroradiol. 2016 Mar 10. PMID: 26965463. Abstract
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J, Chamoux C, Hammès F, Chicoye A PLoS One. 2016; 11(3):e0150703. Epub 2016 Mar 17. PMID: 26987055. Abstract
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH, CAMMS223 Investigators J Neurol Sci. 2016 Apr 15; 363:188-94. Epub 2016 Feb 12. PMID: 27000249. Abstract
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β. Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A CNS Neurol Disord Drug Targets. 2015; 14(6):804-10. PMID: 25801840. Abstract
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis. Strohm T, Chaudhry B, Willis MA, Shook S Mult Scler. 2016 Mar 24. PMID: 27012659. Abstract
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. Signori A, Gallo F, Bovis F, Di Tullio N, Maietta I, Sormani M P Mult Scler Relat Disord. 2016 Mar; 6:57-63. Epub 2016 Feb 02. PMID: 27063624. Abstract
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis]. Borets OG, Govorukhina NF, Zverev KV, Boiko AN Zh Nevrol Psikhiatr Im S S Korsakova. 2016; 116(2. Vyp. 2. Rassejannyyj skleroz):63-67. PMID: 27070363. Abstract
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. Hu X, Shang S, Nestorov I, Hasan J, Seddighzadeh A, Dawson K, Sperling B, Werneburg B Br J Clin Pharmacol. 2016 Apr 8. PMID: 27060836. Abstract
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj K, Skoromets A, Stolyarov I, Bass A, Sullivan H, et al. Neurology. 2012 Apr 3; 78(14):1069-78. Epub 2012 Mar 21. PMID: 22442431. Abstract
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, et al. Pharmacogenomics J. 2016 Mar 22. PMID: 27001119. Abstract